647 related articles for article (PubMed ID: 27217694)
1. HER2 testing in gastric cancer: An update.
Abrahao-Machado LF; Scapulatempo-Neto C
World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
[TBL] [Abstract][Full Text] [Related]
2. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.
Jørgensen JT
World J Gastroenterol; 2014 Apr; 20(16):4526-35. PubMed ID: 24782605
[TBL] [Abstract][Full Text] [Related]
3. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
4. HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.
Grillo F; Fassan M; Sarocchi F; Fiocca R; Mastracci L
World J Gastroenterol; 2016 Jul; 22(26):5879-87. PubMed ID: 27468182
[TBL] [Abstract][Full Text] [Related]
5. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
[TBL] [Abstract][Full Text] [Related]
6. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
8. A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.
Subasinghe D; Acott N; Kumarasinghe MP
Gastrointest Endosc; 2019 Jul; 90(1):44-54. PubMed ID: 30928424
[TBL] [Abstract][Full Text] [Related]
9. Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.
Wang YK; Chen Z; Yun T; Li CY; Jiang B; Lv XX; Chu GH; Wang SN; Yan H; Shi LF
World J Gastroenterol; 2015 Apr; 21(15):4680-7. PubMed ID: 25914479
[TBL] [Abstract][Full Text] [Related]
10. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
[TBL] [Abstract][Full Text] [Related]
11. HER2 testing in gastric cancer: a practical approach.
Rüschoff J; Hanna W; Bilous M; Hofmann M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
Mod Pathol; 2012 May; 25(5):637-50. PubMed ID: 22222640
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
14. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
15. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
16. The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
[TBL] [Abstract][Full Text] [Related]
17. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Shah MA; Kang YK; Thuss-Patience PC; Ohtsu A; Ajani JA; Van Cutsem E; Hoersch S; Harle-Yge ML; de Haas SL
Gastric Cancer; 2019 Jul; 22(4):803-816. PubMed ID: 30706247
[TBL] [Abstract][Full Text] [Related]
18. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
Pietrantonio F; Caporale M; Morano F; Scartozzi M; Gloghini A; De Vita F; Giommoni E; Fornaro L; Aprile G; Melisi D; Berenato R; Mennitto A; Volpi CC; Laterza MM; Pusceddu V; Antonuzzo L; Vasile E; Ongaro E; Simionato F; de Braud F; Torri V; Di Bartolomeo M
Int J Cancer; 2016 Dec; 139(12):2859-2864. PubMed ID: 27578417
[TBL] [Abstract][Full Text] [Related]
19. Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
Kijima T; Arigami T; Uenosono Y; Hiraki T; Yanagita S; Matsushita D; Okubo K; Shimonosono M; Ishigami S; Maemura K; Tanimoto A; Natsugoe S
Anticancer Res; 2020 Jan; 40(1):75-80. PubMed ID: 31892554
[TBL] [Abstract][Full Text] [Related]
20. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]